Crossmark

GDF-15 and risk stratification in atrial fibrillation

Crossref DOI link: https://doi.org/10.1038/nrcardio.2014.190

Published Online: 2014-11-25

Published Print: 2015-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Marín, Francisco

Roldán, Vanessa
License Information

Text and Data Mining valid from 2014-11-25
More Information

Article History

First Online: 25 November 2014

Competing interests

: F.M. has received funding for research, consultancy, and lecturing from Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo. V.R. has received funding for consultancy and lecturing from Bayer, Boehringer Ingelheim, and Bristol-Myers Squibb.